Lexeo Therapeutics (LXEO) Interest Expenses (2022 - 2026)
Lexeo Therapeutics recorded quarterly Interest Expenses of $17000.0 in Q1 2026, down 15.0% quarter-over-quarter from $20000.0 in Q4 2025, and down 39.29% year-over-year from $28000.0 in Q1 2025.
Lexeo Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $17000.0 for Q1 2026.
- In Q1 2026, Interest Expenses fell 39.29% year-over-year to $17000.0; the TTM figure through Mar 2026 stood at $84000.0 (down 34.38% YoY), while the FY2025 annual figure was $95000.0, down 30.66% from the prior year.
- Interest Expenses came in at $17000.0 for Q1 2026 at Lexeo Therapeutics, down from $20000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $54000.0 in Q4 2022 to a low of $17000.0 in Q1 2026.
- A 5-year average of $35800.0 and a median of $35000.0 in 2024 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses jumped 79.31% in 2023 and slumped 40.0% in 2024, its largest moves.
- Lexeo Therapeutics' Interest Expenses stood at $54000.0 in 2022, then dropped by 7.41% to $50000.0 in 2023, then plunged by 40.0% to $30000.0 in 2024, then tumbled by 33.33% to $20000.0 in 2025, then declined by 15.0% to $17000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $17000.0, $20000.0, and $22000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Lexeo Therapeutics | 392.12 Mn | 199.07 Mn | - | 17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Sep 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Jun 30, 2024 | 35,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Mar 31, 2024 | 37,000.00 |
| Dec 31, 2023 | 50,000.00 |
| Dec 31, 2023 | 50,000.00 |
| Sep 30, 2023 | 52,000.00 |
| Sep 30, 2023 | 52,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Dec 31, 2022 | 54,000.00 |
| Sep 30, 2022 | 29,000.00 |
| Sep 30, 2022 | 29,000.00 |